Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months. Wall Street analysts have a consensus Strong Buy rating on the stock and project a further 120% upside as of the close on January 12.

Recent analyst updates include Evercore ISI’s Gavin Clark-Gartner on December 17, trimming the firm’s price target on the stock to $36 from $38, while maintaining an earlier Outperform rating.

According to TipRanks, the firm praised the company for its functionality and meeting expectations on metrics such as safety and efficacy. Despite the cut, the revised price target represents an upside potential of over 100% from Monday’s close.

Earlier on December 10, Oppenheimer upgraded the stock’s rating to Outperform and lifted its price target to $40 from $11 on December 10, citing the anticipated Phase 3 trial readout for competitor Avidity’s RNA therapy, del-desiran in myotonic dystrophy type 1, in the second half of 2026.

According to Oppenheimer, another significant upside catalyst for Dyne Therapeutics, Inc. (NASDAQ:DYN) this year could be the success of its zeleciment basivarsen therapeutic to treat patients living with myotonic dystrophy type 1 (DM1). Moreover, the likelihood of the FDA reviewing the company’s candidate for Duchenne muscular dystrophy (DMD) could also help the stock rally.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a healthcare company focused on developing treatments for patients of genetically driven neuromuscular diseases.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.